Anterix Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Anterix Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $6.03M | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | $4.19M | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | $1.92M | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | $1.08M | Jun 14, 2023 |
| FY2021 | Mar 31, 2021 | $181.0K | Jun 15, 2021 |
| FY2021 | Dec 31, 2020 | $236.0K | Jun 15, 2021 |
| FY2021 | Sep 30, 2020 | $248.0K | Jun 15, 2021 |
| FY2021 | Jun 30, 2020 | $256.0K | Jun 15, 2021 |
| FY2021 | Mar 31, 2020 | $327.0K | Jun 15, 2021 |
| FY2021 | Dec 31, 2019 | $361.0K | Jun 15, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Mar 31, 2019 | ($391.0K) | May 20, 2019 |
| FY2019 | Dec 31, 2018 | ($113.0K) | May 20, 2019 |
| FY2019 | Sep 30, 2018 | $26.0K | May 20, 2019 |
| FY2019 | Jun 30, 2018 | ($274.0K) | May 20, 2019 |
| FY2019 | Mar 31, 2018 | ($495.0K) | May 20, 2019 |
| FY2019 | Dec 31, 2017 | ($415.0K) | May 20, 2019 |
| FY2019 | Sep 30, 2017 | ($398.0K) | May 20, 2019 |
| FY2019 | Jun 30, 2017 | ($235.0K) | May 20, 2019 |
| FY2018 | Mar 31, 2017 | ($694.0K) | Aug 9, 2018 |
| FY2018 | Dec 31, 2016 | ($497.0K) | Aug 9, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($11.37M) | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | ($9.13M) | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | ($16.32M) | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | ($37.52M) | Jun 14, 2023 |
| FY2021 | Mar 31, 2021 | ($10.94M) | Jun 15, 2021 |
| FY2021 | Dec 31, 2020 | ($12.09M) | Jun 15, 2021 |
| FY2021 | Sep 30, 2020 | ($16.28M) | Jun 15, 2021 |
| FY2021 | Jun 30, 2020 | ($15.13M) | Jun 15, 2021 |
| FY2021 | Mar 31, 2020 | ($11.74M) | Jun 15, 2021 |
| FY2021 | Dec 31, 2019 | ($8.81M) | Jun 15, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($11.71M) | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | ($10.12M) | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | ($16.46M) | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | ($36.85M) | Jun 14, 2023 |
| FY2023 | Mar 31, 2021 | ($54.81M) | Jun 14, 2023 |
| FY2022 | Mar 31, 2020 | ($37.53M) | May 26, 2022 |
| FY2020 | Mar 31, 2019 | ($42.74M) | May 28, 2020 |
| FY2019 | Mar 31, 2018 | ($31.73M) | May 20, 2019 |
| FY2019 | Mar 31, 2017 | ($32.78M) | May 20, 2019 |
| FY2018 | Mar 31, 2016 | ($21.93M) | Aug 9, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.74M | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | $5.70M | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | $4.44M | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | $3.59M | Jun 14, 2023 |
| FY2023 | Mar 31, 2021 | $4.34M | Jun 14, 2023 |
| FY2022 | Mar 31, 2020 | $2.95M | May 26, 2022 |
| FY2020 | Mar 31, 2019 | $2.29M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $2.35M | May 20, 2019 |
| FY2019 | Mar 31, 2017 | $2.32M | May 20, 2019 |
| FY2018 | Mar 31, 2016 | $1.32M | Aug 9, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($29.26M) | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | $41.99M | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | ($27.25M) | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | $17.91M | Jun 14, 2023 |
| FY2023 | Mar 31, 2021 | ($9.96M) | Jun 14, 2023 |
| FY2022 | Mar 31, 2020 | ($27.82M) | May 26, 2022 |
| FY2020 | Mar 31, 2019 | ($23.09M) | May 28, 2020 |
| FY2019 | Mar 31, 2018 | ($21.99M) | May 20, 2019 |
| FY2019 | Mar 31, 2017 | ($26.50M) | May 20, 2019 |
| FY2018 | Mar 31, 2016 | ($19.79M) | Aug 9, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $87.0K | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | $307.0K | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | $2.13M | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | $1.05M | Jun 14, 2023 |
| FY2023 | Mar 31, 2021 | $230.0K | Jun 14, 2023 |
| FY2022 | Mar 31, 2020 | $464.0K | May 26, 2022 |
| FY2020 | Mar 31, 2019 | $724.0K | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $950.0K | May 20, 2019 |
| FY2019 | Mar 31, 2017 | $1.64M | May 20, 2019 |
| FY2018 | Mar 31, 2016 | $9.08M | Aug 9, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $333.10M | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | $324.89M | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | $278.56M | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | $278.04M | Jun 14, 2023 |
| FY2022 | Mar 31, 2021 | $253.06M | May 26, 2022 |
| FY2021 | Mar 31, 2020 | $267.40M | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | $196.75M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $220.34M | May 20, 2019 |
| FY2018 | Mar 31, 2017 | $245.49M | Aug 9, 2018 |
| FY2017 | Mar 31, 2016 | $274.05M | Jun 6, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $176.50M | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | $163.86M | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | $98.77M | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | $91.75M | Jun 14, 2023 |
| FY2022 | Mar 31, 2021 | $40.55M | May 26, 2022 |
| FY2021 | Mar 31, 2020 | $22.33M | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | $15.99M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $11.81M | May 20, 2019 |
| FY2018 | Mar 31, 2017 | $17.59M | Aug 9, 2018 |
| FY2017 | Mar 31, 2016 | $11.86M | Jun 6, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $156.60M | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | $161.03M | Jun 24, 2025 |
| FY2025 | Mar 31, 2023 | $179.79M | Jun 24, 2025 |
| FY2024 | Mar 31, 2022 | $186.30M | Jun 26, 2024 |
| FY2023 | Mar 31, 2021 | $212.51M | Jun 14, 2023 |
| FY2023 | Mar 31, 2020 | $245.07M | Jun 14, 2023 |
| FY2022 | Mar 31, 2019 | $180.76M | May 26, 2022 |
| FY2020 | Mar 31, 2018 | $209.30M | May 28, 2020 |
| FY2019 | Mar 31, 2017 | $227.90M | May 20, 2019 |
| FY2019 | Mar 31, 2016 | $262.19M | May 20, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($391.94M) | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | ($372.17M) | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | ($338.37M) | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | ($313.83M) | Jun 14, 2023 |
| FY2022 | Mar 31, 2021 | ($260.35M) | May 26, 2022 |
| FY2021 | Mar 31, 2020 | ($205.91M) | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | ($168.46M) | May 28, 2020 |
| FY2019 | Apr 1, 2018 | ($126.47M) | May 20, 2019 |
| FY2019 | Mar 31, 2018 | ($127.24M) | May 20, 2019 |
| FY2018 | Mar 31, 2017 | ($102.67M) | Aug 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $47.37M | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | $60.58M | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | $43.18M | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | $105.62M | Jun 14, 2023 |
| FY2022 | Mar 31, 2021 | $117.54M | May 26, 2022 |
| FY2021 | Mar 31, 2020 | $137.45M | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | $76.72M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $98.32M | May 20, 2019 |
| FY2018 | Mar 31, 2017 | $124.08M | Aug 9, 2018 |
| FY2017 | Mar 31, 2016 | $153.46M | Jun 6, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | (2) | Jun 14, 2023 |
| FY2023 | Mar 31, 2021 | (3) | Jun 14, 2023 |
| FY2022 | Mar 31, 2020 | (2) | May 26, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | (2) | Jun 14, 2023 |
| FY2023 | Mar 31, 2021 | (3) | Jun 14, 2023 |
| FY2022 | Mar 31, 2020 | (2) | May 26, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 18.61M | Jun 24, 2025 |
| FY2025 | Mar 31, 2024 | 18.45M | Jun 24, 2025 |
| FY2024 | Mar 31, 2023 | 18.92M | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | 18.38M | Jun 14, 2023 |
| FY2022 | Mar 31, 2021 | 17.67M | May 26, 2022 |
| FY2021 | Mar 31, 2020 | 17.18M | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | 14.74M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | 14.49M | May 20, 2019 |
| FY2018 | Mar 31, 2017 | 14.36M | Aug 9, 2018 |
| FY2017 | Mar 31, 2016 | 14.30M | Jun 6, 2017 |